Filtered By:
Management: Funding

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 373 results found since Jan 2013.

Researchers receive NIH funding to develop data-driven strategies in COVID-19 fight
(University of South Carolina) UofSC researchers from its Big Data Health Science Center initiative have received $1.25 million in grant funding from the NIH National Institute of Allergy and Infectious Diseases (NIAID) to develop a data-driven system to track COVID-19 in South Carolina.
Source: EurekAlert! - Infectious and Emerging Diseases - July 8, 2020 Category: Infectious Diseases Source Type: news

Johnson & Johnson Announces European Commission Approval for Janssen ’s Preventive Ebola Vaccine
Discussions with the U.S. Food and Drug Administration (FDA) have taken place to define the required data set for filing US licensure. About Janssen’s Ebola Vaccine Regimen The Janssen preventive Ebola vaccine regimen, Ad26.ZEBOV and MVA-BN-Filo, utilizes a non-replicating viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response.Janssen’s vaccine regimen ori...
Source: Johnson and Johnson - July 1, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Moderna Plans To Start Phase 3 Testing of its COVID-19 Vaccine Candidate in July
This study will include more people who might be a high risk of exposure to COVID-19, such as health care workers and residents in long-term care facilities. In June, Moderna became one of five vaccine developers chosen to be part of President Trump’s Operation Warp Speed program to speed development of a COVID-19 vaccine. The selection qualifies Moderna to receive federal government funding to continue development of vaccine, conduct tests, as well as scale up manufacturing to meet the goal of beginning to inoculate 300 million people beginning early next year. Moderna said it plans to deliver 500 million to 1 billi...
Source: TIME: Health - June 11, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson Receives Positive CHMP Opinion for Janssen ’s Investigational Preventive Ebola Vaccine Regimen
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order to trigger an immun...
Source: Johnson and Johnson - May 29, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Study To Investigate Coronavirus Spread Among Children
BOSTON (CBS) – A new study underway could help figure out why children are not getting as sick from coronavirus. Researchers are enrolling 6,000 people from 2,000 families and they will look at the percentage of kids infected who actually develop symptoms. The families are already participating in federally-funded pediatric research studies in 11 cities, including Boston. The researchers will also study if there is any difference in those numbers for children who have asthma or other allergies. The National Institute of Allergy and Infectious Diseases (NIAID), led by Dr. Anthony Fauci, is sponsoring and funding the s...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 5, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated Local Coronavirus Source Type: news

‘This Is Really Life or Death.’ For People With Disabilities, Coronavirus Is Making It Harder Than Ever to Receive Care
Jeiri Flores is normally a busy, upbeat 29-year-old. But amid the COVID-19 pandemic, her go-to thought has been dark. “If I get this,” she thinks, “I’m gonna die.” This is not an unfounded fear. Flores has cerebral palsy, uses a wheelchair and needs assistance with everyday tasks, including making food and getting dressed. Her disability means it’s tougher for her immune system to kick illnesses; she’s still recovering from a bout of pneumonia she had in January. So beating COVID-19 could easily mean a protracted battle and months in a hospital—a prospect that comes with a c...
Source: TIME: Health - April 24, 2020 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized COVID-19 Source Type: news

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

NIDCR's Spring 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News CDC’s COVID-19 Guidance for Dental Settings  Dental health care personnel can find COVID-19-related information on the CDC’s Division of Oral Health website, which offers guidance and resources for clinics and health care facilities and recommendations for respondi...
Source: NIDCR Science News - March 27, 2020 Category: Dentistry Source Type: news

Masqueraders of Angioedema after a Dental Procedure
This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Source: Annals of Allergy, Asthma and Immunology - March 19, 2020 Category: Allergy & Immunology Authors: Ivan T. Lee, Masaki Arioka, Sara H. Kleinman, Yael Gernez Tags: Challenging Clinical Cases Source Type: research

Africa: Human Trial of Investigational COVID-19 Vaccine Begins
[NIH] Seattle -A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID's Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years
Source: AllAfrica News: Health and Medicine - March 18, 2020 Category: African Health Source Type: news

What the U.S. Needs to do Today to Follow South Korea ’s Model for Fighting Coronavirus
The United States has a narrow window of opportunity to determine the fate of its coronavirus crisis. Will we end up looking like Italy or South Korea? Italy’s health system has imploded under the strain of new cases and the shortage of ventilators means doctors must make agonizing decisions on who to save and who to let die. In contrast, South Korea acted swiftly and boldly to “flatten the curve”— the government did everything it could to slow the rate of increase and so reduce the burden of the illness on the country’s clinics and hospitals. Right now, the number of new cases of confirmed in...
Source: TIME: Health - March 17, 2020 Category: Consumer Health News Authors: Gavin Yamey Tags: Uncategorized COVID-19 Source Type: news

New AIBS Report on Biological Sciences in the President ' s FY 2021 Budget
A new report from the American Institute of Biological Sciences (AIBS) provides an analysis of the President’s fiscal year (FY) 2021 budget request for biological sciences research and education. The report provides an overview and analysis of the budget request for several federal agencies and programs, including the National Science Foundation, National Institutes of Health (NIH), National Institute of Standards and Technology, United States Geological Survey, Department of Energy Office of Science, National Oceanic and Atmospheric Administration, and Environmental Protection Agency, among others. Most federal s...
Source: Public Policy Reports - March 17, 2020 Category: Biology Authors: AIBS Source Type: news

New Tests Enter the Scene as COVID-19 Rages On
Tests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the latest with diagnostic contributions. Waltham, MA-based Thermo Fisher is the second company to be granted an Emergency Use Authorization for a commercially developed COVID-19 test. MD+DI reported Roche received this designation late last week too for the cobas SARA-COV-2 test. In a press release, Thermo Fisher said the authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab...
Source: MDDI - March 16, 2020 Category: Medical Devices Authors: Omar Ford Tags: IVD Regulatory and Compliance Source Type: news

NIH clinical trial of investigational vaccine for COVID-19 begins
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against COVID-19 has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), is funding the trial. KPWHRI is part of NIAID's Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today.
Source: EurekAlert! - Infectious and Emerging Diseases - March 16, 2020 Category: Infectious Diseases Source Type: news

Occupational exposures and idiopathic pulmonary fibrosis
Purpose of review A recent meta-analysis of data from international case–control studies reports a population attributable fraction of 16% for occupational factors in the cause of idiopathic pulmonary fibrosis (IPF). Smoking, genetic factors and other prevalent diseases only partly explain IPF, and so this review aims to summarize recent progress in establishing which occupational exposures are important in cause. Recent findings IPF is a rare disease, although it is the commonest idiopathic interstitial pneumonia. Epidemiological study suggests that incidence of IPF is increasing, particularly in older men. There a...
Source: Current Opinion in Allergy and Clinical Immunology - February 28, 2020 Category: Allergy & Immunology Tags: OCCUPATIONAL DISEASE: Edited by Susan M. Tarlo and Piero Maestrelli Source Type: research